Influenza A NP Antibody (9G8): sc-101352

Influenza A NP Antibody (9G8) is a mouse monoclonal IgG2a kappa light chain antibody that detects the nucleoprotein (NP) of Influenza A virus by western blotting (WB), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-Influenza A NP antibody (9G8) is available in a non-conjugated form, specifically designed for researchers studying the Influenza A virus, which is a negative-sense, single-stranded, segmented RNA virus primarily hosted by birds but capable of infecting various mammalian species. The nucleoprotein (NP) plays a crucial role in the viral life cycle, as NP is essential for the encapsidation of the viral RNA genome, forming ribonucleoprotein complexes that are vital for replication and transcription. NP is located in the nucleus and cytoplasm of infected cells, where NP interacts with the viral RNA and other proteins to facilitate the assembly of new virions. Understanding the localization and function of NP is important for developing antiviral strategies, as NP is a key target for therapeutic intervention. Influenza A viruses are classified into subtypes based on their hemagglutinin and neuraminidase proteins, and NP′s interaction with these components is critical for the virus′s ability to infect host cells and evade the immune response.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Influenza A NP Antibody (9G8) References:

1. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.  |  Skehel, JJ. and Wiley, DC. 2000. Annu Rev Biochem. 69: 531-69. PMID: 10966468
2. Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state: stability and energetics of the hemagglutinin.  |  Huang, Q., et al. 2003. Biochim Biophys Acta. 1614: 3-13. PMID: 12873761
3. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion.  |  Takeda, M., et al. 2003. Proc Natl Acad Sci U S A. 100: 14610-7. PMID: 14561897
4. Completion of trimeric hairpin formation of influenza virus hemagglutinin promotes fusion pore opening and enlargement.  |  Borrego-Diaz, E., et al. 2003. Virology. 316: 234-44. PMID: 14644606
5. Oligomerization of fusogenic peptides promotes membrane fusion by enhancing membrane destabilization.  |  Lau, WL., et al. 2004. Biophys J. 86: 272-84. PMID: 14695269
6. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.  |  Altstein, AD., et al. 2006. Arch Virol. 151: 921-31. PMID: 16292596
7. Structural basis of immune recognition of influenza virus hemagglutinin.  |  Wilson, IA. and Cox, NJ. 1990. Annu Rev Immunol. 8: 737-71. PMID: 2188678
8. A Novel Antiviral Target Structure Involved in the RNA Binding, Dimerization, and Nuclear Export Functions of the Influenza A Virus Nucleoprotein.  |  Kakisaka, M., et al. 2015. PLoS Pathog. 11: e1005062. PMID: 26222066
9. Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice.  |  Hinkula, J., et al. 2019. Vaccines (Basel). 7: PMID: 31315253
10. Influenza virus A pathogenicity: the pivotal role of hemagglutinin.  |  Webster, RG. and Rott, R. 1987. Cell. 50: 665-6. PMID: 3304656
11. Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport.  |  Gething, MJ., et al. 1986. Cell. 46: 939-50. PMID: 3757030
12. Immunogenic structure of the influenza virus hemagglutinin.  |  Green, N., et al. 1982. Cell. 28: 477-87. PMID: 6176330

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Influenza A NP Antibody (9G8) has 24 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Influenza A NP Antibody (9G8) Specifications

Alternate Product Name: Influenza A nucleoprotein (NP)

Product Clone Name: 9G8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids:

Epitope Target: Influenza A NP

Epitope Species: Influenza A virus

Product Reactivity/Detection: nucleoprotein (NP)

Species Reactivity/Detection: Influenza A virus

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, ELISA

Vialing Information: Each vial contains 50 µg IgG_2a kappa light chain in 500 µl of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 24 citations in various scientific publications

Available Conjugates/Forms for Influenza A NP Antibody (9G8): N/A